Executive Team
Dr. Carole Spangler Vaughn holds a Ph.D. in Biophysics (Johns Hopkins University) and an MBA (University of Washington). She has spent over 25 years in the life science industry, mostly at start-ups, bringing oncology products to market.
Jessica Urban has over 25 years of experience in Medical Device Product Development including roles in Management, Business Development, Program Management, Quality, Regulatory, and Engineering.
Paul Klein spent 40-years at GE and GE Healthcare in various positions globally. He is an experienced marketer with B2B and B2C expertise in durables, CPG, and medical products.
Nathan Dale is an experienced medical device engineer with nearly 30 years of expertise in product design, development, and manufacturing across implantable, disposable, and surgical technologies.
Martin Simonetti has had a long and successful career in the life sciences, serving as CFO and CEO. He is currently the CEO of PBS Biotech. He received an MS from the Univ of California, Davis and an MBA from the Univ of Santa Clara.
Mr. Ron Myers (Business/Legal Advisor) has broad experience in M&A, licensing, litigation and intellectual property, including more than 20 years experience in intellectual property acquisition, enforcement and defense in the biotech and pharmaceutical fields.
Advisors
Dr. Noah Kolb (Medical Advisor) is a neurologist at The University of Vermont Medical Center and assistant professor at the UVM College of Medicine Department of Neurology in Burlington, VT. His research focuses on chemotherapy-induced neuropathy.
Jennifer Gewandter, PhD, MPH (Medical Advisor) is an Assistant Professor in the Department of Anesthesiology and Perioperative Medicine at the University of Rochester and an Associate Director of the FDA Public-Private partnership, ACTTION. Her research is focused on optimizing clinical trials for pain and peripheral neuropathy treatments as well as researching interventions for chemotherapy-induced peripheral neuropathy.
Hope Rugo , M.D., is division chief of breast medical oncology and a professor at City of Hope, where she directs the Women’s Cancers Program and oversees national research and clinical care initiatives. A globally recognized leader in breast cancer and clinical trial design, she has helped establish new standards of care through pivotal trials, while also advancing toxicity-reducing innovations such as scalp cooling. With over 500 peer-reviewed publications, major leadership roles within ASCO, and numerous international awards, Dr. Rugo is deeply committed to expanding access to innovative, patient-centered breast cancer therapies worldwide.
Dr. Giancarlo Moscol (Medical Advisor) is a breast cancer oncologist at MD Anderson Cancer Center in Houston, Texas. Dr. Moscol received his MD at Universidad Nacional Mayor de San Marcos in Peru, followed by a residency at Albert Einstein Medical Center.